Biologics and the treatment of chronic rhinosinusitis

Journal of Allergy and Clinical Immunology

Volumn 131, Issue 1, 2013, Pages 117-118

  Kern, Robert C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

asthma; Chronic rhinosinusitis; nasal polyps

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; OMALIZUMAB; PLACEBO; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN;

AIRWAY; ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; ATOPY; BASOPHIL; CARDIOVASCULAR DISEASE; CHRONIC RHINOSINUSITIS; CLINICAL PROTOCOL; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ENDOSCOPIC SINUS SURGERY; EOSINOPHIL; EOSINOPHILIA; HUMAN; MAST CELL; NEOPLASM; NONHUMAN; NOSE POLYP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TH2 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; FEMALE; HUMANS; MALE; NASAL POLYPS;

EID: 84871825280     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.11.021     Document Type: Editorial

References (14)

1. P. Gevaert, L. Calus, T. Van Zele, K. Blomme, N. De Ruyck, and W. Bauters Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma J Allergy Clin Immunol 131 2013 110 116
2. J.M. Pinto, N. Mehta, M. DiTineo, J. Wang, F.M. Baroody, and R.M. Naclerio A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis Rhinology 48 2010 318 324
3. W.J. Fokkens, V.J. Lund, J. Mullol, C. Bachert, I. Alobid, and F. Baroody The European position paper on rhinosinusitis and nasal polyps Rhinol Suppl 23 2012 1 298
4. C. Lamblin, P. Gosset, F. Salez, L.M. Vandezande, T. Perez, and J. Darras Eosinophilic airway inflammation in nasal polyposis J Allergy Clin Immunol 104 1999 85 92
5. B. Chipps, M. Filiomeni, and S. Spector Omalizumab: an update on safety and efficacy in moderate to severe asthma Allergy Asthma Proc 33 2012 337 385
6. W. Busse, R. Buhl, C. Fernandez Vidaurre, M. Blogg, J. Zhu, and M. Eisner Omalizumab and the risk of malignancy: results from a pooled analysis J Allergy Clin Immunol 129 2012 983 989
7. A.A. Long, J.E. Fish, A. Rahamaoui, M.K. Miller, M.S. Bradley, H.N. Taki, and A.N. Demeo Baseline characteristics of patients enrolled in EXCELS: a cohort study Ann Allergy Asthma Immunol 103 2009 212 219
8. P. Gevaert, D. Lang-Loidolt, A. Lackner, H. Stammberger, H. Staudinger, and T. Van Zele Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps J Allergy Clin Immunol 118 2006 1133 1141
9. P. Gevaert, N. Van Bruaene, T. Cattaert, K. Van Steen, T. Van Zele, and F. Acke Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis J Allergy Clin Immunol 128 2011 989 995
10. B. Bochner, and G. Gleich What targeting eosinophils has taught us about their role in diseases J Allergy Clin Immunol 126 2010 16 25
11. P.C. Avila Does anti-IgE therapy help in asthma? Efficacy and controversies Annu Rev Med 58 2007 185 203
12. T. Takabayashi, A. Kato, A.T. Peters, L. Suh, R. Carter, and J. Norton Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps J Allergy Clin Immunol 130 2012 410 420.e5
13. R. Schleimer, A. Kato, and R.C. Kern Eosinophils in CRS J. Lee, H. Rosenberg, Eosinophils in health and disease 2012 Elsevier Amsterdam
14. T. Kiwamoto, N. Kawasaki, J.C. Paulson, and B.S. Bochner Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions Pharmacol Ther 135 2012 327 336